DB13164InvestigationalSmall molecule
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita... Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim.
- Mechanism
- Curator reviewed · 1 reference
Olmutinib covalently binds a cysteine residue near the kinase domain of mutant EGFRs to prevent phosphorylation of the receptor. This inhibits receptor signalling as phosphorylation is necessary for recruitment of signalling cascade proteins.
- Primary indication
- For use in treatment of metastatic T790M mutation positive non-small cell lung cancer.Curator reviewed
- Formula / weight
- C26H26N6O2S · 486.59 g/mol (avg)
- Code names
- BI-1482694 · HM-61713
Resolves to
Clinical / RWD
Structure
InChIKey
FDMQDKQUTRLUBU-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=CC=C(NC2=NC(OC3=CC=CC(NC(=O)C=C)=C3)=C3SC=CC3=N2)C=C1Targets
What you can answer from here — as of February 21, 2021
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Olmutinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account